Strategic Joint Ventures for Clients

Takeda Chemical : Abbott Laboratories

TAP Pharmaceuticals was initially formed to apply a modest FDA-approved product line from Takeda Chemical, to a joint venture formed with a well-established USA company. Takeda's choices were limited by product life-cycle consideration, imposed by approval of a singular ethical offering. Going direct with a $40 Million product, though with strong Women's Therapeutic indications and growing target market demographics, did not predict an acceptable outcome. Abbott represented a strong Marketing/Sales infrastructure to ramp up revenue, as well as attractive R&D plus Regulatory Affairs support to explore future line extensions. Over time TAP Pharmaceuticals entered Oncology Therapeuitics, and revenue exceeded $4 Billion.